Risk of death due to cardiovascular disease among patients with RA, according to known predictors and mannose-binding lectin. Univariate Cox proportional hazards regression analysis.
| Variables | N | HR (95% CI) | p |
|---|---|---|---|
| Duration of disease (decade) | 229 | 0.9 (0.7–1.3) | 0.75 |
| Erosive disease | 229 | 1.3 (0.6–2.8) | 0.49 |
| HAQ | 224 | 1.7 (1.1–2.7) | 0.02 |
| Extraarticular manifestations | 219 | 1.4 (0.6–3.4) | 0.46 |
| IgM RF-positive | 224 | 2.5 (0.9–7.1) | 0.09 |
| CRP > 100 mg/dl | 221 | 2.3 (1.1–4.7) | 0.03 |
| HLA-DR1/HLA-DR4 | 224 | 1.7 (0.7–4.2) | 0.22 |
| Smoking | 207 | 1.4 (0.7–3.0) | 0.40 |
| Nutrition below normal | 216 | 2.5 (1.1–5.7) | 0.03 |
| Nutrition above normal | 216 | 0.9 (0.4–2.0) | 0.77 |
| Hypertension | 227 | 1.2 (0.6–2.5) | 0.66 |
| Diabetes | 229 | 2.9 (1.2–7.1) | 0.02 |
| MTX treatment | 229 | 0.8 (0.3–1.8) | 0.53 |
| Anti-TNF-α drugs | 229 | 0.4 (0.1–1.4) | 0.17 |
| MBL2 genotype A/A* | 229 | 1.8 (0.9–3.7) | 0.11 |
| MBL2 genotype YA/YA** | 215 | 2.0 (1.0–4.1) | 0.04 |
| Serum MBL | 209 | 1.3 (1.0–1.5) | 0.02 |
↵* Comparing MBL2 genotype A/A with A/O + O/O.
↵** Comparing MBL2 genotype YA/YA with YA/XA + XA/XA + YA/O+ XA/O + O/O. HR: hazard ratio; HAQ: Health Assessment Questionnaire; RF: rheumatoid factor; CRP: C-reactive protein; HLA: human leukocyte antigen; MBL: mannose-binding lectin; MTX: methotrexate; TNF-α: tumor necrosis factor-α.